阳光诺和(688621.SH)：BTP4327获得药物临床试验批准通知书

智通财经03-04

智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及子公司江苏诺和必拓新药研发有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目BTP4327的临床试验申请获得批准。本次递交的BTP4327为化药2类改良型新药，拟申报适应症为治疗高血压，以降低血压。本品用于单药治疗不能充分控制血压的患者。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2616533018?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-04 17:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616533018","market":"us","top_or_hot":-1,"title":"阳光诺和(688621.SH)：BTP4327获得药物临床试验批准通知书","media":"智通财经","content":"<div>\n<p>智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及子公司江苏诺和必拓新药研发有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目BTP4327的临床试验申请获得批准。本次递交的BTP4327为化药2类改良型新药，拟申报适应症为治疗高血压，以降低血压。本品用于单药治疗不能充分控制血压的患者。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1409981.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阳光诺和(688621.SH)：BTP4327获得药物临床试验批准通知书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阳光诺和(688621.SH)：BTP4327获得药物临床试验批准通知书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 17:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1409981.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及子公司江苏诺和必拓新药研发有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目BTP4327的临床试验申请获得批准。本次递交的BTP4327为化药2类改良型新药，拟申报适应症为治疗高血压，以降低血压。本品用于单药治疗不能充分控制血压的患者。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1409981.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688621","symbol_name":"阳光诺和","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1409981.html","article_id":"2616533018","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616533018","pubTimestamp":1772616322,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及子公司江苏诺和必拓新药研发有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目BTP4327的临床试验申请获得批准。本次递交的BTP4327为化药2类改良型新药，拟申报适应症为治疗高血压，以降低血压。本品用于单药治疗不能充分控制血压的患者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688621":"阳光诺和","BK0216":"研究试验"},"translate_title":"Sunshine Novo (688621. SH): BTP4327 obtained drug clinical trial approval notice","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688621":1.5},"content_text":"智通财经APP讯，阳光诺和(688621.SH)发布公告，近日，公司及子公司江苏诺和必拓新药研发有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研项目BTP4327的临床试验申请获得批准。本次递交的BTP4327为化药2类改良型新药，拟申报适应症为治疗高血压，以降低血压。本品用于单药治疗不能充分控制血压的患者。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616533018","isCrawlerRequest":true}